J. Creemers

PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses

C. Figdor, V. Cerundolo, M. Diken, 2021, Frontiers in Immunology.

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery

C. Figdor, N. Mehra, W. Gerritsen, 2020, Journal for ImmunoTherapy of Cancer.

Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination

Inge M. N. Wortel, C. Figdor, K. Verrijp, 2022, Journal for ImmunoTherapy of Cancer.

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

J. Witjes, C. Figdor, J. Barentsz, 2019, Journal of Immunotherapy for Cancer.

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination

C. Figdor, C. Punt, J. D. de Wilt, 2016, Oncoimmunology.

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol

C. Figdor, M. Middleton, P. Ottevanger, 2021, BMJ Open.

Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

D. Somford, M. Janssen, N. Mehra, 2020, Frontiers in Oncology.

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients

C. Figdor, C. Punt, R. Koornstra, 2016, Journal of immunotherapy.